Skip to Main Content

Paper Details

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
J Clin Oncol
503
2018
Author NameAffiliation
Lecia V SequistYale Cancer Center, Vanderbilt University Medical Center David Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Dana-Farber Cancer Institute Rebecca Heist and Lecia V. Sequist, Massachusetts General Hospital, H. Lee Moffitt Cancer Center & Research Institute, Memorial Sloan-Kettering Cancer Center, Carolina BioOncology Institute, University of Michigan, The Christ Hospital Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
David C SmithYale Cancer Center, Vanderbilt University Medical Center David Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Dana-Farber Cancer Institute Rebecca Heist and Lecia V. Sequist, Massachusetts General Hospital, H. Lee Moffitt Cancer Center & Research Institute, Memorial Sloan-Kettering Cancer Center, Carolina BioOncology Institute, University of Michigan, The Christ Hospital Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 1 - 2

Datasets